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Abstract
Background: The administration of rituximab (RTX) in vivo results in B-cell depletion, but evidence for multiple 
mechanisms of action have been reported. Surprisingly, B cell depletion produced a response in patients with 
polymyositis, which is characterized as a T cell-mediated autoimmune disorder with biopsy findings similar to Miyoshi 
myopathy (MM). Indeed, in dysferlinopathies, there is evidence of immune system involvement including the presence 
of muscle inflammation and a down regulation of the complement inhibitory factor, CD55.
Methods: Two patients were treated with four weekly infusions of RTX 375 mg/m2. To measure the improvement in 
muscle strength after treatment, the isometric hand grip maximal voluntary contraction (MVC) was measured by load 
cell four times during treatment, and again after one year. In order to assess the reproducibility of our grip assessment, 
we determined the hand MVC analysis in 16 healthy subjects. Moreover, we measured the number of B cells present in 
patients by flow cytometric analysis during the course of treatment.
Results: The analysis of B cell number during the course of treatment showed that CD20- and CD19-positive cells were 
depleted to 0-0.01%. The decrease in B cells was followed by an improvement in the mobility of the pelvic and 
shoulder girdles as shown by the MRC%. The MVC values of both patients began at values lower than normal whereas 
during treatment patients had improved percentage of muscle strength. The strength peak in both patients coincided 
with the minimum B cell values. There were no severe adverse events associated with an infusion of RTX.
Conclusion: We consider the increase in muscle strength observed in both treated patients to be a consequence of 
their treatment with RTX. To our knowledge, these are the first cases of increased muscle strength in patients with MM. 
Furthermore, the results of this study indicate that B cell depletion with RTX may be useful in the treatment of patients 
affected by MM, suggesting a possible role for B cells in the pathophysiology of this muscle disorder.
Background
Dysferlinopathies are recessive inherited muscular dys-
trophies caused by mutation of the dysferlin gene (DYSF)
mapped to human chromosome 2p13 [1]. The two main
phenotypes recognized in such conditions are Miyoshi
myopathy (MM), a disorder that preferentially affects the
distal musculature, and Limb-Girdle muscular dystrophy
type 2B (LGMD2B), a disorder that is characterized by
involvement of the pelvic and shoulder girdles [2]. The
DYSF gene encodes a 230-kDa protein, which is normally
expressed in the sarcolemma in skeletal muscle and
which is absent in patients with LGMD2B or MM. Lack
of DYSF may cause faulty myoblast fusion, impairing
muscle regeneration. Both phenotypes can be found
among patients belonging to the same family; thus, they
appear to share the same mutation [2]. A biopsy will not
detect specific alterations such as variation in fibre size or
necrotic and regenerating fibres with increased connec-
tive tissue. The specific diagnosis is completed by the use
of an immunoblotting technique with anti-DYSF anti-
bodies, which shows an absence of the protein. The
immunostaining of sections can also reveal the lack of
protein.
In MM, the disease onset generally occurs in the late
teens with an initial involvement of the distal muscles in
the posterior compartments of the lower limb. A com-
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mon early symptom is the inability of patients to stand on
their tiptoes and to toe walk. Although DYSF is also
expressed in cardiomyocytes, there is no evidence of car-
diac muscle dysfunction in DYSF-deficient patients.
Miyoshi myopathy is associated with markedly elevated
creatine kinase levels (10 times normal) and dystrophic
changes in muscle histopathology.
The biopsy may also show an inflammatory infiltrate
which mimics the histopathologic picture of an inflam-
matory myopathy [3]. There are several signs that inflam-
mation contributes to dysferlinopathy [4]. Up to now,
several studies have reported a prominent inflammatory
response in dysferlinopathy patients. In the animal model
of DYSF deficiency, i.e. the mutant SJL mouse strain, the
disease process was initially considered an 'inflammatory'
form of muscular dystrophy. Moreover, a down-regula-
tion of the complement inhibitory factor, CD55 in the
skeletal muscle of mice and patients with DYSF-deficient
muscular dystrophy was recently demonstrated, resulting
in an increased susceptibility of DYSF-deficient human
myotubes to complement attack in vitro [5]. Since there
are no effective therapies to treat MM [6], and the possi-
ble therapeutic effects of intravenous immunoglobulins
(i.v. Ig) is the inhibition of complement factors C4 and
C5, treatment with i.v. Ig was tested in one patient with
LGMD2B [7]. After the treatment, the patient experi-
enced a transient improvement in muscle strength in a
few muscles [7]. These finding suggest a relationship
between the absence of DYSF and immune system abnor-
malities in muscle, and open the possibility of testing new
immunosuppressive treatments in dysferlinopathies. Tak-
ing these aspects into consideration, rituximab therapy
may be an attractive treatment option for several reasons:
muscle infiltrates in dysfelinopathic patients are often dif-
ficult to distinguish from those of polymyositis patients,
and recent studies reported an improvement in muscle
strength without significant side effects in patients with
polimyositis treated with rituximab [8]. Moreover, the
onset of action of rituximab seems to be relatively rapid
and its short-term safety profile is favorable [9]. Experi-
ence from the lymphoma literature suggests a low inci-
dence of adverse effects with the medication, which is
mostly related to infusion reactions after the first dose
[10]. Rituximab is a human/murine chimeric monoclonal
antibody, directed against CD20-positive B cells, that has
shown promising activity in the treatment of a broad
array of autoimmune diseases including rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE), idio-
pathic thrombocytopenic purpura, and IgM-mediated
neuropathies [11]. Administration of rituximab in vivo
results in B-cell depletion, but evidence for multiple
mechanisms of action are reported and it remains unclear
which mechanisms are most important in patients [11].
In fact, it is somewhat surprising that B cell depletion
elicited a striking response in patients with PM, which is
characterized as a T cell-mediated autoimmune disorder
[ 8 ] .  W e  d e s c r i b e  t w o  p a t i e n t s  w i t h  M M  i n  w h o m  t h e
muscle biopsies exhibited an evident myopathic pattern,
with necrosis and an increase in interstitial inflammatory
infiltrate. After one year of follow-up, the two treated
patients did not develop side effects and showed a partial
recovery of their distal muscle strength, suggesting that
the use of rituximab in these patients is safe and partially
active. To our knowledge, this is the first case of increased
muscle strength in patients with MM who received an
experimental treatment.
Methods
Study group and inclusion criteria
A medical and medication history was taken, and a com-
plete physical and neurologic examination and an evalua-
tion of muscle strength by manual testing were
conducted. A complete blood cell count, electrolyte lev-
els, creatine phosphokinase (CPK) levels, quantitative
immunoglobulins, and CD20 and CD19 levels were
recorded. Patients were excluded if they were known to
have severe heart disease (heart failure, arrhythmias, cor-
onaropathies, or myocardial infarct in the past 6 months),
symptomatic macroglobulinemia, hypersensitivity to any
component of rituximab, or pre-existing known malig-
nancy requiring treatment. Patients were also excluded if
they had active infections, hepatitis B positivity, hepatitis
C positivity, or human immunodeficiency virus positivity.
Patients were recruited after obtaining informed consent.
The end point of this study was improvement in muscle
strength after treatment with rituximab at the 1-year fol-
low up. The primary efficacy outcome parameter in this
study was maximal hand grip strength measured by load
cell (BC302; DS Europe, Milan, Italy) [12]. This was then
compared with standardized normal levels for age and
sex to derive a percentage of normal strength. Treatment
was considered to be effective if muscle strength was
improved by >5%.
Patient 1 was a 41-year-old man who was diagnosed
with MM at 22 years of age. He was born at term follow-
ing an unremarkable pregnancy. His motor development
was normal. There was no family history of muscle dis-
eases. The onset of symptoms began at the age of 16 years
when he started to complain of difficulty climbing stairs
and standing on his toes. He developed progressive walk-
ing difficulties and lost independent ambulation at the
age of 30 years. He also developed upper limb involve-
ment. At the time of diagnosis, his right quadriceps mus-
cles showed evidence of a myopathic pattern with
necrosis and an increased interstitial cellularity. Immu-
nostaining and western-blotting showed an absence ofLerario et al. BMC Musculoskeletal Disorders 2010, 11:157
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DYSF protein. A chromosomal analysis showed a
homozygous deletion of exon 55 (6233del CCTTCAGC)
of the DYSF gene.
In order to determine a baseline for the distal muscle
force of the superior arms, the patient's hand grip muscle
strength was assessed before (-365, -300, -150, and -90
days) and at times that coincided with the four weekly
rituximab infusions (0, 7, 14, 21 days). The same analysis
was done 338 days after the first infusion of rituximab.
Patient 2 was a 30-year-old man diagnosed with MM at
the age of 17 years. He was born at term following an
unremarkable pregnancy. His motor development was
normal. A family history of muscle disease was not
reported. The onset of symptoms began at the age of 16
years when he started to complain of difficulty standing
on his toes and rigidity of the gastocnemii muscles. At the
same age, hyperCKemia was observed. From the age of 18
years, the patient developed progressive weakness in the
lower limbs, which was more pronounced in the distal
compartments, with gait difficulties. In the following
years, he also manifested upper limb girdle involvement.
A t  t h e  t i m e  o f  d i a gn os is,  h is  ri g h t  q ua d ri c e ps  m us c l e s
showed evidence of a myopathic pattern with fiber size
variability, increased connective tissue, necrosis, and
increased interstitial cellularity. Immunostaining and
western-blotting showed an absence of DYSF protein.
The chromosomal analysis demonstrated a homozygous
deletion of exon 22 (20077delC) corresponding to an
amino acid substitution, His693ThrfsX4.
In order to define a baseline for the distal muscle force
of the superior arms, the patient's hand grip muscle
strength was assessed before (-365, -300, -150 and -90
days) and at times that coincided with the four weekly
rituximab infusions (0, 7, 21, 35 days). The same analysis
was done 223 days after the first infusion of rituximab. In
both patients 1 and 2, we assessed the MRC% index
before, during, and after the treatment as indicated in the
literature [13].
Administration of rituximab
Patients were required to provide written informed con-
sent. They received four intravenous infusions of ritux-
imab given at weekly intervals. Premedication with
acetaminophen and diphenhydramine was given at each
infusion to attenuate possible infusion-related reactions.
During each infusion, patients were treated with ritux-
imab 375 mg/m2. In all cases, the first infusion of ritux-
imab was administered intravenously at an initial rate of
50 mg/hour, and in the absence of hypersensitivity or
infusion-related events, the infusion rate was increased in
50-mg/hour increments every 30 minutes to a maximum
of 400 mg/hour. Subsequent infusions of rituximab were
administered at an initial rate of 100 mg/hour and
increased in 100-mg/hour increments at 30-minute inter-
vals to a maximum of 400 mg/hour, as tolerated [14].
Hand grip maximal voluntary contraction (MVC)
The maximal voluntary contraction (MVC) isometric,
developed from the opponent muscles of the thumb and
the flexor muscles of the hand that are involved in hand
grip, was measured using one load cell (BC 302; DS
Europe, Milan, Italy) [12,15]. The patients were seated in
a chair with the left elbow placed on a padded support at
a 90° angle. Then they gripped the load cell (BC302; DS
Europe, Milan, Italy) between the phalanx of the first (I)
finger and the phalanxes of the II, III, IV, and V fingers
(Figure 1). The motor task required the subject to exert a
hand grip that activated the opponent muscles of the
thumb and the flexor muscles of the hand. To determine
the MVC force, patients were instructed to increase the
force from zero to maximum and to hold it for 3 minutes.
Patients performed ten MVC trials subdivided into two
sessions and rested for 60 minutes between successive tri-
als. The mean of the best five performances was taken as
the MVC force and used as the reference value to calcu-
late the target force. To estimate intra-subject reproduc-
ibility of the measured isometric MVC, the MVC was
determined twice over a period of 8 days in 16 healthy
subjects using the same procedure. The signal from the
load cell (range: 0-60 kg; sensitivity, 2 mV/V; total error, <
0.5%; repeatability, < 0.1%) was preamplified and low-
pass filtered (< 1000 Hz) with an analogue amplifier [Sig-
nal Conditioner Cambridge 1902; Cambridge Electronic
Design (CED), Cambridge, England]). The output signal
was digitized (Cambridge Micro 1402; CED) with a sam-
pling rate of 2500 Hz and 12-bit quantization with a 5 V
range. The digitized signal was stored on a personal com-
puter and displayed using Spike2 software (version 5.11;
CED) [12].
Results
Patients
Data from 2 patients, both males aged between 30 and 40
years, were obtained. Both patients had a muscle disorder
Figure 1 The load cell. Illustration of the load cell used for the hand 
grip muscle strength measurements used in the study.Lerario et al. BMC Musculoskeletal Disorders 2010, 11:157
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of long duration (15-20 years), and both were symptom-
atic with reduced muscle strength in the distal muscles of
the lower limbs and above. Before treatment, a neurologi-
cal examination of patient 1 showed an upper-limb, MRC
grade 2/3 muscle strength at the girdle muscles and grade
1/2 distally. The proximal lower extremities were more
severely impaired: strength was 1/2 in the ileopsoas, and
1 in the quadriceps femoris and tibialis anterior. After the
treatment, patient 1 showed an upper-limb, MRC grade 3
muscle strength in the girdle muscles, and grade 2 dis-
tally. The proximal lower extremities strength was 2 in
the ileopsoas and 1.5 in the quadriceps femoris and tibia-
lis anterior. Before treatment, patient 2's neurological
examination showed an upper-limb MRC grade-3 muscle
strength in the girdle muscles and grade 2/3 distally. The
proximal lower extremities were more severely impaired:
his strength was 2 in the ileopsoas, 1.5 in the quadriceps
femoris, and 1 in the tibialis anterior. Following treat-
ment, patient 2 had an upper-limb MRC grade 4 muscle
strength in the girdle muscles and grade 3\2 distally. The
proximal lower extremities were 3 in the ileopsoas, 2 in
the quadriceps femoris, and 1.5 in the tibialis anterior.
Therefore, both patients had an increase in MRC% [15]
(4% for patient 1 and 5% for patient 2). Both patients
showed constant normal CPK levels following treatment
with rituximab. Patients were given weekly rituximab
treatments for four weeks then were followed for one
year.
Reproducibility
In order to assess the reproducibility of our grip assess-
ment, we determined the hand MVC analysis in a group
of 16 healthy subjects, with two readings taken over an 8-
day period. After 8 days, differences between values were
not found to be statistically significant (P < 0.05) suggest-
ing that any statistically significant increase in strength in
the patients will reflect a real change in muscle strength.
Muscular strength
The first patient was evaluated four times during the
course of treatment and again 338 days after the first
infusion. The initial force percentage in both patients,
13% of normal strength for patient 1 and 58% of normal
strength for patient 2, was measured -365, -300, -150, and
-90 days before the beginning of treatment in four sepa-
rate hand MVC analysis sessions (Figure 2). Patient 1 was
evaluated four times during the course of the study (Fig-
ure 2). Maximal improvement in patient 1 occurred seven
days after the first infusion, when his muscle strength was
24% of normal, which represented an 11% increase over
baseline. Subsequent to the third infusion of rituximab
(14 days after the first infusion), the MVC was 21%, and
after the fourth infusion (21 days after the first infusion)
the MVC was 19%. This muscle percentage strength was
retained 338 days after the beginning of treatment.
Patient 1's increase in strength was about 10% during the
first infusion, suggesting a transient effect of the therapy
in the recovery of strength, probably favored by the dele-
tion of B cells. Patient 2 was evaluated three times during
the course of treatment and again 223 days after the first
rituximab infusion (Figure 2). Maximal improvement
occurred after the third infusion (35 days after the first
infusion), when the patient's muscle strength was 78% of
normal strength, which represented a 20% increase over
baseline. Twenty one days after the first infusion, his
MVC was 76% and 223 days after the first infusion it was
70%. Both patients were surveyed 21 days from the begin-
ning of treatment and percentage of force was between
15% and 20% compared with healthy in patient 1, while
these values were around 72% for patient 2. Thus, the
improvement in both patients exceeded the prospec-
tively-defined minimum criterion of effectiveness (>5%
increase in muscle strength). An assessment conducted at
338 days for patient 1 and 223 days for patient 2 after
treatment with rituximab shows that the percentage of
force levels was higher than the values obtained after the
first rituximab infusion. A comparison of the values
Figure 2 The time course of changes in the hand-grip muscle 
strength of patients 1 and 2 before and after treatment with 
rituximab. The right and left hand-grip muscle strength is expressed 
as a percentage of the mean values obtained from a group of 16 
healthy male subjects, regarded as baseline, and taken with the value 
100%. The upper and lower left panels show the right and left hand 
grip muscle strength values of patients 1 and 2 at days -365, -300, -150 
and -90 before the treatment. Patient 1 was evaluated four times dur-
ing the course of treatment and again after about one year. The per-
centage improvement in the patient was around 13% compared to 
the normal reference value, and the highest percentage increase in 
strength occurred after 7-14 days. Patient 2 was evaluated three times 
during the course of treatment and again approximately eight months 
after treatment. The percentage improvement of the patient com-
pared to the normal reference value was around 58% and the highest 
percentage increase of distal muscle strength (20%) occurred after 35 
days.Lerario et al. BMC Musculoskeletal Disorders 2010, 11:157
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obtained with the hand MVC analysis in both patients
indicated that patient 2 had a better response to treat-
ment with rituximab than did patient 1 (Figure 3).
B cell depletion
The number of B cells measured by flow cytometric anal-
ysis during the course of treatment showed that CD20-
and CD19-positive cells were depleted to 0-0.01% during
the treatment, whereas the percent before treatment was
2.9-7.3% (Figure 3).
Following rituximab infusion, patient 1 exhibited a total
depletion of B cells as measured by flow cytometric anal-
ysis of CD19 and CD20 levels. Three hundred thirty eight
days after the first infusion for patient 1 and 223 days
after the first infusion for patient 2, circulating B cells lev-
els returned to normal. In patient 2, B lymphocytes rap-
idly decreased after the first administration of rituximab
and remained nearly undetectable during the entire treat-
ment course. One year after the infusion, the patient's
CD19- and CD20-positive cells recovered to the normal
range.
Safety
Rituximab was well tolerated by both patients during
treatment and 1 year after completing the treatment.
During the first infusion, patient 2 experienced an epi-
sode of edema glottis. After momentary interruption of
the infusion of the drug, the event resolved spontane-
ously in 30 minutes. The laboratory parameters were nor-
mal.
Discussion
Currently, there are no effective therapies to treat MM
[3]. The use of corticosteroids, particularly dantrolene
[6], has led to a slight increase in strength with relative
decreases in the levels of CPK. Unfortunately, the many
side effects associated with therapy outweigh the modest
benefits. The small sample number of patients tested
with rituximab therapy must be considered when assess-
ing the results of our study. Indeed, considering the epi-
demiology of dysferlinopathies (approximately 1/400,000)
[2], the preference was to proceed with a pilot study in
which each patient was considered his or her own con-
trol. In this way, the activity of the drug (strength and
concentration of B lymphocytes) over a one-year period
was assessed in order to control for any placebo effects.
Rituximab is a genetically engineered (chimeric
murine/human) monoclonal antibody directed against
the CD20 antigen on B cells [16]. The CD20 surface anti-
gen is widely expressed during B cell ontogeny but is not
found on hemopoietic stem cells, pro-B cells, mature
plasma cells, or other normal tissues [17-19]. CD20 regu-
lates early steps in activation and differentiation, and may
function as a calcium ion channel [20,21]. Rituximab's
property of depleting CD20-positive B cells while sparing
stem and plasma cells has been used successfully in the
treatment of non-Hodgkin's lymphoma (NHL) [22] and
i n  a u t o i m m u n e  d i s o r d e r s  s u c h  a s  R A ,  S L E ,  a n d  I g M -
mediated neuropathies [23-27].
Our one-year study indicates that B cell depletion coin-
c i d e s  w i t h  i m p r o v e m e n t s  i n  m u s c l e  s t r e n g t h  i n  M M
patients. Despite the depression of circulating B cell lev-
els, no prominent infections occurred. The results sup-
port the notion that B cells play a pivotal role in the
pathophysiology of MM. In addition, the duration of B
cell depletion and associated reduction in symptoms fol-
lowing a single course of treatment with rituximab in
patients with MM is consistent with that seen in other
conditions such as NHL and IgM-mediated neuropathies.
Both MM patients started with muscle strength values
lower than normal (13% in patient 1 and 58% in patient
2). During treatment, both patients experienced an
increase in the percentage of muscle strength compared
with baseline values. The peak strength for patient 1
increased to about 24% compared with the normal refer-
Figure 3 Correlation between the course of the hand-grip muscle 
strength and the number of B cells. The percentages of hand-grip 
muscle strength of the two treated patients was measured during the 
four weekly infusions of rituximab (indicated as I, II, III, IV, respectively) 
and after 338 (for patient 1) and 223 (for patient 2) days of the first in-
fusion of rituximab. The right and left hand grip muscle strength is ex-
pressed as a percentage of the mean values obtained from a group of 
16 healthy male subjects, which was considered as a value of 100%, 
and was regarded as the baseline value of the patient. The correlation 
between the course of the hand-grip muscle strength and the B cells 
levels show that the depletion of the B cells corresponds to an increase 
in the hand-grip muscle force, whereas the hand-grip muscle strength 
returned to the baseline levels as B cell became reconstituted.Lerario et al. BMC Musculoskeletal Disorders 2010, 11:157
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ence value, and the peak strength for patient 2 increased
to 78% compared with the normal reference value. The
better clinical and MVC% improvement in patient 2 com-
pared with patient 1, who also had a lower response in
percentage terms from patient 2, can probably be
explained by the different degrees of muscle degeneration
at baseline between these patients. Patient 1 experienced
the clinical presentation of muscular dystrophy for a
greater number of years and may have consequently
developed a higher degree of deterioration of his muscle
tissue with less chance for recovery.
The development of muscle strength fluctuates over
time by 10-20% and, although the muscle strength was
always greater than the baseline level, the overall clinical
p i ct u r e  o f  t h e  pa t i e n ts  was  a l m os t  u n c h a n g ed .  I n  fa ct,
from both descriptions given by the patients and clinical
examinations of several muscle districts, substantial
improvements were not detected. The possible reasons
for this variability are many. On the one hand, the vari-
ability may have been related to the method of quantita-
t i v e  m e a s u r e m e n t .  I t  w o u l d  t a k e ,  b e f o r e  t r e a t m e n t ,  a
greater number of manual strength tests in the patients to
consolidate the phenomenon of the motor task that, on
the one hand, because of variation of the results as it
increases the number of trials and other decreases vari-
ability minimizing compensating movements made by
the patient. It must also take into account the state of
health and the lifestyle of the patient when the tests were
performed, since the standardization of quantitative evi-
dence of strength is important. The MVC% increases
coincided with increases in the MRC% [13] of 4% for
patient 1 and 5% for patient 2. The largest increase in the
MRC assessment of a single muscle was detected on the
distal muscles of the upper limbs. The natural history of
MM is characterized by a progressive loss of muscle force
with no natural or temporary recovery, as reported in the
literature. Thus, the increase in the hand-grip muscle
strength observed in both patients and the improvement
in the global MRC% can be considered a consequence of
the treatment with rituximab. The good tolerability of
rituximab in these two MM patients is in accordance with
the experience in RA, SLE, and DM [13,28,29] in that
there were no severe adverse events associated with the
treatment. Such reactions emerge less frequently in
patients with autoimmune conditions compared with
patients with NHL [27]. In NHL patients, lysis of tumor
burden may contribute to the mostly mild-to-moderate
transient infusion reactions seen in these patients, the
frequency of which is greater during the first infusion
than in subsequent infusions [21,30].
The results of this study indicate that B cell depletion
with rituximab appears to be useful in the treatment of
patients with MM, and suggest a possible role of B cells in
the pathophysiology of this muscle disorder. Moreover,
the absence of side effects in these patients shows that
this treatment is safe. Further investigation is needed to
u n d e r s t a n d  t h e  r o l e  o f  B  c e l l  d e p l e t i o n  i n  t h e  m u s c l e
pathology of MM patients and to determine the effective-
ness of rituximab as a treatment for MM.
Conclusion
The natural history of MM is characterized by a progres-
sive loss of muscle force with no natural, even temporary,
recovery. Thus, we can consider the increase in hand grip
muscle strength observed in both treated patients and the
improvement of the global MRC% as a consequence of
the treatment with rituximab. The results of this study
indicate that B cell depletion with rituximab appears to
be active in the treatment of MM patients, and suggests a
possible role of B cells in the pathophysiology of this mus-
cle disorder. Moreover, the absence of side effects during
the course of this study demonstrates that this treatment
is safe. Further investigations are needed to understand
the role of B depletion in the muscle pathology of MM
patients and to determine the effectiveness of rituximab
as treatment for MM. To our knowledge, this is the first
treatment showing increased muscle strength in patients
with MM.
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